Interpace Biosciences (IDXG) replaces 2019 equity and stock purchase plans
Rhea-AI Filing Summary
Interpace Biosciences, Inc. (IDXG) filed an amended current report to document stockholder approval and adoption of its new 2026 Benefit Plans. At the August 20, 2026 annual meeting, stockholders approved the 2026 Equity Incentive Plan and the 2026 Employee Stock Purchase Plan.
The 2026 Equity Incentive Plan replaces the company’s 2019 Equity Incentive Plan, and the 2026 Employee Stock Purchase Plan replaces the 2019 Employee Stock Purchase Plan, as amended. No further equity awards will be granted under the 2019 Equity Incentive Plan and no further purchases will occur under the 2019 ESPP. Detailed terms of the new plans are provided in the company’s July 7, 2026 definitive proxy statement and in plan forms incorporated by reference as exhibits.
Positive
- None.
Negative
- None.
8-K Event Classification
2 items: 5.02, 9.01
2 items
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
Annual meeting date: August 20, 2026
Proxy statement filing date: July 7, 2026
Legacy plan year: 2019
3 metrics
Annual meeting date
August 20, 2026
Date stockholders approved the 2026 Benefit Plans
Proxy statement filing date
July 7, 2026
Date of definitive proxy statement describing 2026 Benefit Plans
Legacy plan year
2019
Year of the equity and ESPP plans being replaced by the 2026 Benefit Plans
Key Terms
Equity Incentive Plan, Employee Stock Purchase Plan, emerging growth company
3 terms
Equity Incentive Plan financial
"the adoption of the Company’s 2026 Equity Incentive Plan (the “2026 Incentive Plan”)"
An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.
Employee Stock Purchase Plan financial
"and 2026 Employee Stock Purchase Plan (the “2026 ESPP”)"
An employee stock purchase plan is a company program that lets workers buy shares through small payroll deductions, often at a discount to the market price and after a set offering period. Think of it like a workplace savings plan that turns into ownership: it encourages employees to share in the company’s success and can create predictable buying or selling of stock that investors watch because it affects supply, demand and employee incentives.
emerging growth company regulatory
"or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
FAQ
What did Interpace Biosciences (IDXG) change with its 2026 Benefit Plans?
Interpace Biosciences’ stockholders approved the 2026 Equity Incentive Plan and 2026 Employee Stock Purchase Plan at the August 20, 2026 annual meeting. These plans collectively form the 2026 Benefit Plans and replace the company’s prior 2019 equity and employee stock purchase plans.
Which prior plans are being replaced by the new 2026 plans at IDXG?
The 2026 Equity Incentive Plan replaces the 2019 Equity Incentive Plan, and the 2026 Employee Stock Purchase Plan replaces the 2019 Employee Stock Purchase Plan, as amended. After adoption, no further awards or purchases will occur under the 2019 plans.
When did Interpace Biosciences’ stockholders approve the 2026 Benefit Plans?
Stockholders of Interpace Biosciences approved the 2026 Benefit Plans at the company’s annual meeting of stockholders held on August 20, 2026. The amended report documents this adoption, which had been previously conditioned on stockholder approval.
Will any further grants be made under Interpace Biosciences’ 2019 Equity Incentive Plan?
No. The filing states that, with adoption of the 2026 Equity Incentive Plan, no further grants of equity awards will be made under the 2019 Equity Incentive Plan.
Where can investors find the detailed terms of IDXG’s 2026 Benefit Plans?
The filing incorporates by reference the full text of the 2026 Benefit Plans from the company’s definitive proxy statement filed July 7, 2026, under Proposals 3 and 4, and from Exhibits 10.1 and 10.2 to this report.
AI-generated analysis. How Rhea-AI works. Not financial advice.
